Lung Cancer

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Will graphic images and stronger warnings decrease cigarette smoking?

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results

Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

Patients screened with low-dose helical computed tomography (CT) reduced their risk of dying of lung cancer by 20% compared with chest x-ray.

Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study

Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit

Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.

In an effort to draw attention to the dangers of tobacco, the FDA has mandated the inclusion of graphic warnings to cigarette packs and advertisements.

Results of a phase II trial showed that former smokers had significant regression of endobronchial dysplasia when treated with iloprost.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC

New results appear to undercut the longstanding notion that individuals who smoke menthol cigarettes have a higher risk of lung cancer than those who smoke nonmenthol cigarettes

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Patients with node-negative, locally advanced lung tumors who undergo induction chemoradiotherapy appear to survive significantly longer than patients who undergo surgical resection without induction chemoradiotherapy

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer